Author of

• 10720

  +

  P1.09 - Poster Session 1 - Combined Modality (ID 212)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Combined Modality
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10741

    +

    P1.09-021 - Is PET/CT a better tool than CT in response evaluation and follow-up of stage III non-small cell lung cancer after chemoradiotherapy? (ID 3220)

    09:30 - 09:30  |  Author(s): B. Aktas
    • Abstract

    Background
    Although pretreatment evaluations are well defined for the diagnosis of stage III NSCLC, we have very little data about the follow-up of these patients after completion of therapy. No documented standards for surveillance were set in the NCCN, ACCP or ESMO guidelines. To determine if there is a survival difference in stage III NSCLC patients who were followed by PET/CT or CT after chemoradiotherapy.

    Methods
    Data from 50 patients who were treated with CRT in Marmara University Medical Oncology clinics between 2003-2012 were retrospectively reviewed. All patients were followed-up by CT or PET/CT. Median age was 57 (range 29-73 years), 90% were male, and PS was 0 in 74%. Adenocarcinoma was seen in 28% and squamous cell carcinoma in 48%. PET/CT was done in 86% of patients during metastatic workup. Median follow-up was 17 months. Median overall survival for all patients was 26 months (range 3-70 months) and progression free survival was 10 months (3-63 months).

    Results
    PET/CT was used in 58% of the patients to evaluate response and was done a median of 6 months after the first treatment. Eight patients had complete, 23 had partial response and 4 had progressive disease. Median survival was 18 months in patient who were followed by CT scans, whilst the survival in the group who had PET/CT was 30 months (p:0.098). Thirtythree patients relapsed on follow-up; of these 28 presented with symptoms, 17 was detected with CT, 5 with MRI of brain and 12 with PET/CT.

    Conclusion
    Response evaluation with PET/CT after CRT in stage III NSCLC might prolong survival in this selected group of patients. But during the follow-up period PET/CT might not be as beneficial as expected, because most of the patients present with symptoms on relapse. Further clinical well designed studies should be done in this field, because usage of PET/CT for follow-up is increasing in the entire world. PET/CT might be unnecessary in the follow-up of stage III NSCLC patients after initial response evaluation.